Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia

References

• Population Division US Census Bureau. Table1: Annual estimates of the population by sex and five-year age groups for the United States: April 1, 2000 to July 1, 2007. NC-EST2007–01. May 2008
   Google Scholar
• Archer DF, Furst K, Tipping D, Dain MP, Vandepol C. A randomized comparison of continuous combined transdermal delivery of estradiol-norethindrone acetate and estradiol alone for menopause. CombiPatch Study Group. Obstet Gynecol 1999; 94:498–503
   PubMed Web of Science ®Google Scholar
• Christiansen C, Christensen MS, Larsen NE, Transbol IB. Pathophysiological mechanisms of estrogen effect on bone metabolism. Dose-response relationships in early postmenopausal women. J Clin Endocrinol Metab 1982;55:1124–30
   PubMed Web of Science ®Google Scholar
• Women's Health Initiative. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288: 321–33
   PubMed Web of Science ®Google Scholar
• Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419–27
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. JAMA 2003;289:3243–53
   PubMed Web of Science ®Google Scholar
• Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350:1047–59
   PubMed Web of Science ®Google Scholar
• Li L, Plummer SJ, Thompson CL, et al. A common 8q24 variant and the risk of colon cancer: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 2008;17:339–42
   PubMed Web of Science ®Google Scholar
• Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estrogen-only therapy. Obstet Gynecol 2006;108:1354–60
   PubMed Web of Science ®Google Scholar
• Lacey JV, Mink PJ, Lubin JH, et al. Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 2002;288: 334–41
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321–33
   PubMed Web of Science ®Google Scholar
• Beral V, Bull D, Reeves G. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 2005; 365:1543–51
   PubMed Web of Science ®Google Scholar
• Gambrell RD Jr, Massey FM, Castaneda TA, et al. Use of the progestogen challenge test to reduce the risk of endometrial cancer. Obstet Gynecol 1980;55:732–8
   PubMed Web of Science ®Google Scholar
• Labrie F. Intracrinology. Mol Cell Endocrinol 1991;78:C113–18
   PubMed Web of Science ®Google Scholar
• Labrie F. DHEA after menopause – sole source of sex steroids and potential sex steroid deficiency treatment. Menopause Management 2010;19:14–24
   Google Scholar
• Labrie F, Luu-The V, Bélanger A, et al. Is DHEA a hormone? Starling Review. J Endocrinol 2005;187:169–96
   PubMed Web of Science ®Google Scholar
• Labrie F. Drug Insight: breast cancer prevention and tissue-targeted hormone replacement therapy. Nature Clinical Practice, Endocrinology & Metabolism 2007;3:584–93
   PubMedGoogle Scholar
• Labrie F, Archer D, Bouchard C, et al. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy. Menopause 2009;16:907–22
   PubMed Web of Science ®Google Scholar
• Labrie F, Archer D, Bouchard C, et al. Effect on intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause 2009;16:923–31
   PubMed Web of Science ®Google Scholar
• Labrie F, Archer D, Bouchard C, et al. Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration. Menopause 2009;16:897–906
   PubMed Web of Science ®Google Scholar
• Meisels A. The maturation value. Acta Cytol 1967;11:249
   PubMed Web of Science ®Google Scholar
• Wied GL. Industrial developments in automated cytology as submitted by their developers. Anal Quant Cytol Histol 1993;15:358–70
   PubMed Web of Science ®Google Scholar
• Labrie F, Cusan L, Gomez JL, et al. Effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women. J Steroid Biochem Mol Biol 2008;111:178–94
   PubMed Web of Science ®Google Scholar
• Labrie F, Cusan L, Gomez JL, et al. Corrigendum to: Effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women. J Steroid Biochem Mol Biol 2008; 112:169
   Web of Science ®Google Scholar
• Bachmann GA, Nevadunsky NS. Diagnosis and treatment of atrophic vaginitis. Am Fam Physician 2000;61:3090–6
   PubMed Web of Science ®Google Scholar
• Nachtigall L, Nachtigall M, Goren J, Loewenstein J. Update on vaginal atrophy. Menopause Management 2005;14:17–19
   Google Scholar
• Bachmann G, Lobo RA, Gut R, Nachtigall L, Notelovitz M. Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial. Obstet Gynecol 2008;111:67–76
   PubMed Web of Science ®Google Scholar
• Simon J, Nachtigall L, Gut R, et al. Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet. Obstet Gynecol 2008;112:1053–60
   PubMed Web of Science ®Google Scholar
• Eugster-Hausmann M, Waitzinger J, Lehnick D. Minimized estradiol absorption with ultra-low-dose 10 μg 17β-estradiol vaginal tablets. Climacteric 2010;13:219–27
   PubMed Web of Science ®Google Scholar
• Bachmann GA, Komi JO, Ospemifene Study Group. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause 2010;17:480–6
   PubMed Web of Science ®Google Scholar
• Labrie F, Martel C, Gauthier S, Pelletier G, Sancéau JY. Effect of toremifene and ospemifene, compared to acolbifene, on estrogen-sensitive parameters in rat and human uterine tissues. Horm Mol Biol Clin Invest 2010;1:139–46
   PubMedGoogle Scholar
• Qu Q, Zheng H, Dahllund J, et al. Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats. Endocrinology 2000;141:809–20
   PubMed Web of Science ®Google Scholar
• NAMS. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 Position Statement of the North American Menopause Society. Menopause 2007;14: 357–69
   Web of Science ®Google Scholar
• Wines N, Willsteed E. Menopause and the skin. Australas J Dermatol 2001;42:149–8; quiz 59
   PubMedGoogle Scholar
• Pandit L, Ouslander JG. Postmenopausal vaginal atrophy and atrophic vaginitis. Am J Med Sci 1997;314:228–31
   PubMed Web of Science ®Google Scholar
• Archer DF. Drospirenone-containing hormone therapy for postmenopausal women. Perspective on current data. J Reprod Med 2007;52(2 Suppl):159–64
   PubMed Web of Science ®Google Scholar
• Labrie F, Bélanger A, Bélanger P, et al. Androgen glucuronides, instead of testosterone, as the new markers of androgenic activity in women. J Steroid Biochem Mol Biol 2006;99:182–8
   PubMed Web of Science ®Google Scholar
• Labrie F, Cusan L, Gomez JL, et al. Comparable amounts of sex steroids are made outside the gonads in men and women: strong lesson for hormone therapy of prostate and breast cancer. J Steroid Biochem Mol Biol 2009;113:52–6
   PubMed Web of Science ®Google Scholar
• Labrie F, Cusan L, Gomez JL, et al. Changes in serum DHEA and eleven of its metabolites during 12-month percutaneous administration of DHEA. J Steroid Biochem Mol Biol 2008;110:1–9
   PubMed Web of Science ®Google Scholar
• Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health (Larchmt) 2006;15:35–44
   PubMed Web of Science ®Google Scholar
• Hsia J, Langer RD, Manson JE, et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med 2006;166:357–65
   PubMed Web of Science ®Google Scholar
• Pines A, Sturdee DW, MacLennan AH, et al. The heart of the WHI study: time for hormone therapy policies to be revised. Climacteric 2007;10:267–9
   PubMed Web of Science ®Google Scholar
• Riman T, Dickman PW, Nilsson S, et al. Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. J Natl Cancer Inst 2002;94:497–504
   PubMed Web of Science ®Google Scholar
• Ruttimann J. The menopause brain effect: can hormone therapy help? Endocrine News 2008;15–16
   Google Scholar
• Migeon CJ, Keller AR, Lawrence B, Shepart II TH. Dehydroepiandrosterone and androsterone levels in human plasma. Effect of age and sex: day-to-day and diurnal variations. J Clin Endocrinol Metab 1957;17:1051–62
   PubMed Web of Science ®Google Scholar
• Vermeulen A, Deslypene JP, Schelfhout W, Verdonck L, Rubens R. Adrenocortical function in old age: response to acute adrenocorticotropin stimulation. J Clin Endocrinol Metab 1982;54:187–91
   PubMed Web of Science ®Google Scholar
• Labrie F. DHEA, important source of sex steroids in men and even more in women. Neuroendocrinology, The Normal Neuroendocrine System, Progress in Brain Research. In Martini L, Chrousos GP, Labrie F, Pacak K, Pfaff D, eds. New York: Elsevier; 2010:97–148
   Google Scholar
• Labrie F, Diamond P, Cusan L, et al. Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. J Clin Endocrinol Metab 1997;82:3498–505
   PubMed Web of Science ®Google Scholar
• Schover LR. Androgen therapy for loss of desire in women: is the benefit worth the breast cancer risk? Fertil Steril 2008;90:129–40
   PubMed Web of Science ®Google Scholar
• van Anders SM, Hamilton LD, Schmidt N, Watson NV. Associations between testosterone secretion and sexual activity in women. Horm Behav 2007;51:477–82
   PubMed Web of Science ®Google Scholar
• van Anders SM, Hampson E. Waist-to-hip ratio is positively associated with bioavailable testosterone but negatively associated with sexual desire in healthy premenopausal women. Psychosom Med 2005;67:246–50
   PubMed Web of Science ®Google Scholar